Which statement best describes safety assessment and reporting in clinical trials?

• A. Evaluation of safety information and reporting of adverse events.
• B. Conducting site visits and safety reviews.
• C. Managing trial budgets and timelines.
• D. Final reporting of trial results.

Answer: (A)

The main idea being tested is how safety data are handled during a trial: continuously gathering safety information, assessing it, and reporting adverse events in a timely and appropriate way. In practice, this means every adverse event observed in participants is documented, its seriousness, severity, and possible relation to the investigational product are evaluated, and those findings are reported to the sponsor, ethics committees, and regulatory authorities according to defined timelines. This ongoing safety assessment supports the risk‑benefit evaluation of the trial and can trigger actions such as protocol amendments or stopping rules if safety concerns arise. The other activities described—site visits and safety reviews relate to monitoring oversight, budgeting and timelines concern logistics, and final trial results reporting focuses on outcomes rather than ongoing safety data handling.